High incidence of chromosomal abnormalities at 1p36 and 9p21 in early-stage central type squamous cell carcinoma and squamous dysplasia of bronchus detected by autofluorescence bronchoscopy

Shibukawa, Kiyoko ; Miyokawa, Naoyuki ; Tokusashi, Yoshihiko ; Sasaki, Takaaki ; Osanai, Shinobu ; Ohsaki, Yoshinobu
Abstract. Heavy smokers with central type squamous cell carcinoma (SCC) frequently have multiple cancerous lesions in the bronchus. Autofluorescence bronchoscopy (AFB) is useful in the detection of early bronchogenic cancer and dysplastic lesions. We investigated the loss of heterozygosity (LOH) and microsatellite instability (MSI) and expression of four proteins in 13 early stage SCC (early SCC) and 9 squamous dysplasia detected by AFB and 19 cases of surgically resected invasive SCC (invasive SCC). In early SCC and squamous dysplasia, LOH/MSI of chromosome 1p36 was found in 62 and 33%, respectively, and of 9p21 in 54 and 63%, respectively. TAp73 expression of early SCC and squamous dysplasia was lower than that of normal bronchial epithelium, and p16 expression was not detectable in these lesions. These results suggested that the genetic abnormalities had already developed in the early stage of carcinogenesis of SCC, including squamous dysplasia. The AFB system was able to reveal abnormal autofluorescence in these precancerous lesions, including squamous dysplasia.

Introduction

Lung cancer is the leading cause of cancer death in the industrialized countries including Japan (1). Detection of lung cancers in their early stages is the most significant way to improve the clinical course of the disease. The 5-year survival rates of non-small cell lung carcinoma (NSCLC) are 44-79.5% for stage I, 29-59.9% for stage II, 6-19.3% for stage III and 2-20% for stage IV (2,3). Squamous cell carcinoma (SCC) accounts for almost 30% of all lung cancers (4), and tobacco smoking is associated with an increased risk for bronchogenic SCC (5). Heavy smokers with central type SCC frequently have multiple cancerous lesions in the bronchus. In Japanese, the relative risk of lung cancer for current smokers versus never smokers was estimated to be 4.39 for men and 2.79 for women, especially, the relative risks for SCC were as high as 11.7 and 11.3, respectively (6). Early-stage central type lung cancers are curable with even a low-invasive endobronchial treatment such as a photodynamic therapy (PDT) (7-9) when the cancers are limited to the mucosa, i.e., carcinoma in situ (CIS).

Nearly 90% of pulmonary SCC is located at the central bronchus (10). Examinations to detect central type lung cancers include sputum cytological examination and bronchoscopic examination, and these procedures are well established in terms of screening bronchogenic SCC (11). However, it is often difficult to detect early stage SCC or dysplastic lesions by only white-light bronchoscopy (WLB).

It is reported that autofluorescence bronchoscopy (AFB) systems are useful to detect dysplastic lesions and bronchogenic cancers in situ in the early stages (12-16). Lam et al examined 173 subjects known or suspected to have lung cancer using the light-induced fluorescence endoscopy (LIFE) device (Xillix Technologies Corp., Richmond, BC, Canada) (14,17). They reported that the relative sensitivity of WLB+LIFE vs. WLB alone was 6.3 for intraepithelial neoplastic lesions and that the LIFE system improved the ability to detect dysplastic malignant lesions (14). Chiyoda et al compared the autofluorescence imaging bronchovideoscope (AFI) system (Olympus Optical Corp., Tokyo, Japan) with the LIFE system in 32 patients with suspected cancer, malignant sputum cytology, and known lung cancer (18). The sensitivities of dysplasia detection by LIFE and AFI were 96.7 and 80%, respectively, and the specificities were 36.6 and 83.3%, respectively. Thus, the specificity of AFI was significantly better (p<0.01). Nakanishi et al reported using a color
fluorescence endoscopic system, PDS-2000 (Hamamatsu Photonics K.K., Hamamatsu, Japan) (19,20) that enabled observation of the color autofluorescence from the bronchial wall, and that addition of AFB significantly improved detection of early central lung cancers and dysplastic lesions in comparison with only WLb (21). Therefore, observation of autofluorescence from the bronchial wall seems to improve detection of early bronchogenic cancer.

Human cancers are now widely accepted to be genetic diseases developing through the accumulation of genetic alterations in critical genes. It is reported that human cancers are caused by activation of oncoproteins such as K-ras, c-myc, and bcl-2, and/or inactivation of tumor suppressor genes such as p53, PTEN and APC (22-25). Measurement of loss of heterozygosity (LOH) or microsatellite instability (MSI) is a method of chromosomal analysis using microsatellite markers.

Many studies of LOH/MSI in various cancers have been performed. LOH has been used as an indicator for the targeted deletion of tumor suppressor genes such as FHIT gene at 3p14, p53 gene at 17p13, and CDKN2 gene at 9p21 (26-29). Pan et al studied surgically resected specimens and reported that LOH of 1p, 3p, 5q, 17p and 18q were common in the tobacco smoking-related NSCLC (30). Yoshino et al reported that the incidence of LOH in SCC of the lung was higher than that in adenocarcinoma (31).

To clarify the efficacy of autofluorescence bronchoscopy in the detection of early lung bronchogenic cancer, especially in terms of genetic abnormalities, we analyzed the chromosomal abnormalities and protein expressions in early-stage central type SCC and precancerous lesions that were found by AFB using a polymerase chain reaction (PCR)-LOH/MSI method. Further, we studied the differences of LOH/MSI, protein expression, and pathological findings between early bronchogenic cancers and invasive bronchogenic cancers to reveal the significant genetic alterations in early and advanced bronchogenic cancer.

Materials and methods

Patients and samples

Early-stage central type squamous cell carcinoma and squamous dysplasia. We diagnosed early-stage central type SCC (early SCC) when the characteristics fulfilled both criteria A and B of the Japan Lung Cancer Society (32).

Criteria A (clinical criteria) were normal X-ray examinations of the chest and no lymph node metastases or distant metastases. Criteria B (bronchoscopic criteria) were cancerous lesions located from the trachea to the subsegmental bronchus, the distal margin of cancerous lesions could be visualized by bronchoscopy, the size of cancerous lesions was <2 cm, cancerous lesions were diagnosed as SCC pathologically, and they were limited to the mucosa.

Fifteen patients with early SCC underwent PDT from 2001-2007 at the Asahikawa Medical College Hospital. Among these 15, 13 patients agreed to participate in this study (Table I). Written informed consent was obtained from the patients before pre-PDT bronchoscopy. The study was approved by the ethics committee of the Asahikawa Medical College. All patients were male, and their pack-year indices were >50.

Early SCC lesions and moderate-to-severe dysplastic lesions of the bronchus were collected by biopsy from bronchial lesions that emitted abnormal color fluorescence during examination using the AFB system, PDS-2000. We classified moderate-to-severe dysplastic lesions as squamous dysplasia in the present study. Pathological diagnosis of each lesion was confirmed microscopically by two pathologists according to the World Health Organization criteria. Thirteen early SCC and nine squamous dysplasia were obtained from the 13 cases. These squamous dysplasia were localized to the lobar bronchus or segmental bronchus. Normal bronchial epithelia were also obtained by the bronchial biopsy.

Invasive squamous cell carcinoma. We examined 19 cases of SCC of the lung with interstitial tissue invasion that had been surgically resected in 2004 and 2005 at the Asahikawa Medical College Hospital and that agreed to participate in this study (Table I). The tumors were staged according to the International Union Against Cancer tumor-node-metastasis (TNM) classification system and histologically sub-typed and graded according to the World Health Organization guidelines. Pathological stages of the cancer was 14 stage I, 1 stage II, 3 stage III and 1 stage IV (32).

DNA extraction. We used the laser microdissection and pressure catapulting (LMPC) method (PALM Micro Laser Systems, Germany) to isolate nuclei of cancerous, dysplastic, and normal bronchial epithelial cells from paraffin-embedded tissue specimens. Paraffin-embedded specimens were cut 8 μm thick, and 3000 nuclei were collected by LMPC. DNA was extracted from these nuclei using 100 μl DNA extraction buffer [50 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 0.5% Tween-20, and proteinase K (1 mg/ml)] incubated at 37°C for overnight. After proteinase K heat denaturing, we used 3 μl of this extracted DNA solution (~90 microdissected nuclear DNA) as a PCR template.

Analysis of loss of heterozygosity and microsatellite instability.

Analysis of LOH and MSI was performed by the PCR-LOH/MSI method. We examined two microsatellite loci on
were placed in methanol containing 3% hydrogen peroxide and mounted on silicon-coated glass slides. Deparaffinized sections embedded tissues were sectioned at 4 μm thickness and analyzed by immunohistochemical staining.

Immunohistochemical staining. The antibodies we used in this study were p73 (Calbiochem, Darmstadt, Germany), p16 (Novocastra, Newcastle, UK) and p53 (DakoCytomation, Glostrup, Denmark), and Ki-67 (DakoCytomation) (Table II).

This p53 antibody detected mainly mutated p53. Ki-67 staining, and then washed three times with PBS.

Samples were treated with a primary antibody overnight for p73 and p16 staining, and for 30 min for mutated p53 and Ki-67 staining, and then washed three times with PBS. Envision plus was added for each samples and incubated for 30 min. After washing with PBS three times, sections were immersed in hydrogen peroxidase and 3,3'-diaminobenzidine solution for 2 min. After rinsing with purified water three times, all sections were counterstained with Mayer's hematoxylin and mounted with Entellan-new (Merck, Darmstadt, Germany). Specific staining was identified by the presence of brown reaction products. Control sections resected from other patients with ovarian carcinoma for p73, pancreas carcinoma for p16, colon carcinoma for mutated p53, and tonsil for Ki-67 were incubated with or without primary antibodies, as positive and negative controls, respectively.

Table II. Immunohistochemical antibodies.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Clone</th>
<th>Dilution</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>p73</td>
<td>Ab-4</td>
<td>1:100</td>
<td>Calbiochem</td>
</tr>
<tr>
<td>p16</td>
<td>6H12</td>
<td>1:40</td>
<td>Novocastra</td>
</tr>
<tr>
<td>p53</td>
<td>DO-7</td>
<td>1:50</td>
<td>DakoCytomation</td>
</tr>
<tr>
<td>Ki-67</td>
<td>MIB-1</td>
<td>1:100</td>
<td>DakoCytomation</td>
</tr>
</tbody>
</table>

Immunohistochemical staining. The antibodies we used in this study were p73 (Calbiochem, Darmstadt, Germany), p16 (Novocastra, Newcastle, UK) and p53 (DakoCytomation, Glostrup, Denmark), and Ki-67 (DakoCytomation) (Table II).

To determine LOH, the height of gel peaks was measured in relative fluorescent units. For each informative case (showing two alleles in normal tissue), the height of the major peak of each allele was considered, being consistent with the highest one. A ratio between normal and carcinoma (or dysplasia) tissue peak was calculated as follows: allele ratio = (peak height of normal allele 2/peak height of normal allele 1)/(peak height of carcinoma allele 2/peak height of carcinoma allele 1). LOH event was considered when the allele ratio was <0.5 or >2.0 (33,34).

MSI was defined by existence of additional peaks or displaced peaks, which showed two or more base pair size difference compared with that of the normal bronchial epithelial DNA (35).

Results

PCR-LOH/MSI analysis of early SCC and squamous dysplasia of bronchus detected by AFB. Table III shows the results of PCR-LOH/MSI analysis in early SCC and squamous dysplasia of the bronchus detected by AFB. In 13 DNA samples from lesions with early SCC, LOH/MSI was found in 62% (8/13) for chromosome 1p36 and in 54% (7/13) for 9p21. In nine DNA samples from lesions of squamous dysplasia of the bronchus, we could not amplify one sample for 9p21. LOH/MSI was found in 33% (3/9) and 63% (5/8), respectively. Thus, chromosomal abnormalities of 1p36 and 9p21 were frequently found in DNA samples from early SCC and squamous dysplasia.
Immunohistochemical scoring of early SCC and squamous dysplasia of bronchus detected by AFB. Table IV shows the IHC scores of p73, p16, mutated p53 and Ki-67 proteins in lesions with early SCC or squamous dysplasia of the bronchus. IHC scores for Ki-67 and mutated p53 protein in early SCC and squamous dysplasia were significantly higher than those in the normal bronchial epithelium. In contrast, the IHC score for p73 protein in early SCC and squamous dysplasia was significantly lower than those in the normal bronchial epithelium. There was no significant difference in IHC scores for p16 protein between early SCC or squamous dysplasia and normal bronchial epithelium. When the IHC scores of all early SCC and squamous dysplasia of the bronchus were compared, no statistically significant differences were found.

PCR-LOH/MSI analysis of invasive SCC. Table III shows the results of PCR-LOH/MSI analysis of invasive SCC. In 19 DNA samples from invasive SCC tissues, we were not able...
to amplify three samples for 1p36. LOH/MSI was detected in 44% (7/16) for 1p36 and in 84% (16/19) for 9p21.

**Immunohistochemical scoring of invasive SCC.** Table V shows a summary of IHC scores in invasive SCC. Ki-67 and mutated p53 IHC scores of invasive SCC were significantly higher than those of normal bronchial epithelium. p73 IHC score of invasive SCC was significantly lower than that of normal bronchial epithelium. There was no significant difference in IHC scores for p16 protein between invasive SCC and normal bronchial epithelium.

**Comparison of PCR-LOH/MSI analysis and immunohistochemical scores in early and invasive SCC.** In the PCR-LOH/MSI analysis, the frequencies of LOH/MSI in 1p36 and 9p21 in early SCC and invasive SCC were not statistically different (Table III). No statistically significant differences were found between IHC scores of p73, p16, mutated p53, and Ki-67 of early SCC and invasive SCC (Table VI).

**Discussion**

In this study we revealed that autofluorescence observed on AFB reflected genetic abnormalities in the bronchial epithelium. We investigated the abnormalities of two chromosomal regions and the expression levels of the tumor suppressor gene products in the AFB detectable early bronchogenic lesions. Further, we investigated whether there was a difference in chromosomal abnormalities and protein expression between early and late stages of SCC carcinogenesis by compared with early SCC and invasive SCC. We used the LMPC method because it enabled LOH/MSI analysis of very small pathological samples such as biopsy specimens from the bronchial wall obtained by bronchoscopy. The nuclear DNA examined from SCC, squamous dysplasia, and normal bronchial epithelial cells was confirmed by microscopy. Therefore, the results of LOH/MSI of these lesions could be accurately compared in the present study.

We selected two chromosomal regions, 1p36 and 9p21 in the LOH/MSI analysis. The tumor suppressor genes associated with these sites are p73 and p53, respectively (38,39). p73 was identified as a p53 family member that showed substantial structural and functional homology with p53 (40) and has many p53-like properties; i.e., it binds p53 DNA target sites, transactivates p53-responsive genes, and induces cell cycle arrest or apoptosis by promoting cell cycle progression in the

Table IV. IHC scores of early SCC, squamous dysplasia and normal bronchial epithelium.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Normal</th>
<th>Dysplasia</th>
<th>Early SCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>p73</td>
<td>7.3±0.6</td>
<td>5.0±1.2</td>
<td>5.2±1.9</td>
</tr>
<tr>
<td>p16</td>
<td>0.3±0.8</td>
<td>0.9±1.2</td>
<td>0.9±1.8</td>
</tr>
<tr>
<td>p53</td>
<td>0.4±0.6</td>
<td>2.9±2.4</td>
<td>4.3±3.2</td>
</tr>
<tr>
<td>Ki-67</td>
<td>1.1±1.1</td>
<td>4.5±2.0</td>
<td>5.6±1.9</td>
</tr>
</tbody>
</table>

aNormal bronchial epithelium; bsquamous dysplasia; caverage ± SD. *Considered to be significant (p<0.01). **Considered to be significant (p<0.05).

Table V. IHC scores of invasive SCC and normal bronchial epithelium.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Normal</th>
<th>Invasive SCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>p73</td>
<td>6.4±0.8</td>
<td>4.4±2.0</td>
</tr>
<tr>
<td>p16</td>
<td>0</td>
<td>0.8±2.0</td>
</tr>
<tr>
<td>p53</td>
<td>0</td>
<td>5.1±3.2</td>
</tr>
<tr>
<td>Ki-67</td>
<td>0.6±0.9</td>
<td>6.4±1.1</td>
</tr>
</tbody>
</table>

aNormal bronchial epithelium; baverage ± SD. *Considered to be significant (p<0.01).

Table VI. IHC scores compared with early SCC and invasive SCC.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Early SCC vs. invasive SCCa</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>p73</td>
<td>0.1816</td>
<td></td>
</tr>
<tr>
<td>p16</td>
<td>0.6382</td>
<td></td>
</tr>
<tr>
<td>p53</td>
<td>0.2696</td>
<td></td>
</tr>
<tr>
<td>Ki-67</td>
<td>0.3237</td>
<td></td>
</tr>
</tbody>
</table>

aComparison between early SCC and invasive SCC.
G1/S phase (41,42). p16 is a member of the inhibitors of cyclin-dependent kinases 4 (INK4) family. Other members such as p15, p18 and p19 are structurally related to p16 (43). These proteins inhibit cyclin-dependent kinase (CdK) 4 and CdK6 in the G1 phase.

p73 is expressed as transcriptionally active (TA) and transcriptionally inactive (ΔN) forms (38,42,44,45). TAp73 has a pro-apoptotic activity similar to wild-type p53 (41,42). In contrast, ΔNp73 displays dominant negative behavior against TAp73 and wild-type p53 (46). This protein has been reported to have oncogenic potential (47). The balance between intracellular expression levels of pro-apoptotic TAp73 or p53 and anti-apoptotic ΔNp73 seems to be important in the regulation of cell cycle progression (42). The anti-p73 antibody used in the present study detects only the wild-type TAp73 protein, which plays an important role as a tumor suppressor (38), as described above. Nomoto et al reported frequent allelic loss at the p73 locus at 1p36 in NSCLC, especially in SCC (48).

p16 plays an important role in the arrest of proliferation of cells at senescence (43). LOH at 9p21, absence of p16 expression, and methylation of p16 have been reported in various cancer cell lines. Sharpless et al reported that p16 knockout mice were prone to develop tumors and indicated that this protein has a role as a tumor suppressor (49). Kishimoto et al proposed that LOH at the 9p locus occurred at the earliest stage in the pathogenesis of lung cancer (50). Tissues without p16 expression have been found more frequently in SCC than in adenocarcinoma (51-53).

In the present study, early SCC and squamous dysplasia that emitted abnormal autofluorescence colors had high incidence of chromosomal abnormalities in 1p36 and 9p21 on PCR-LOH/MSI analysis. These results suggested that these chromosomal abnormalities had already developed in the early stages of carcinogenesis of SCC including squamous dysplasia of the bronchus. Expression levels of TAp73 protein in early SCC and squamous dysplasia were significantly lower than that in normal bronchial epithelium. This reduction of TAp73 expression might be related to LOH or MSI of 1p36. Interestingly, our study revealed overexpression of TAp73 protein in the normal bronchial epithelium. It was reported that the expression levels of TAp73 protein are maintained at a low level under normal physiological conditions (42). The majority of normal bronchial epithelium used in this study was obtained from smokers. On the other hand, we examined the expression levels of TAp73 using normal bronchial epithelium obtained from four non-smokers, and found that expression levels of TAp73 in non-smokers were similar to those in smokers. Furthermore, the other normal epithelium from different organs did not express TAp73 detected by IHC staining (data not shown). Our result revealed that DNA repair through the TAp73 pathway had already occurred in the normal bronchial epithelium independent of smoking. The bronchial epithelium could be continuously exposed to a small amount of toxic substances in the air. Therefore, the increased TAp73 expression in our study potentially reflected initiation of bronchial wall damage by toxic substances. Toxic substances in tobacco tar might play a role in the damage on some genes independent of p73 pathway, or as the second hit on bronchogenic carcinogenesis.

Expression of p16 protein was less frequent in early SCC and squamous dysplasia, although Ki-67 expression increased in these tissues. The decrease of p16 expression was considered to relate to LOH or MSI of 9p21. These results suggested that LOH/MSI of 9p21 causes a loss of p16 expression, and finally carcinogenesis in SCC (50). Further, the expression of mutated p53 was high not only in early and invasive SCC but also in squamous dysplasia. These results confirmed previous observations of a significant association between p53 mutations and LOH of 9p, resulting in accumulation of mutated p53 protein in NSCLC (54,55).

To clarify the relationship of LOH/MSI and carcinogenesis of pulmonary SCC, we compared the early SCC and invasive SCC. The PCR-LOH/MSI analysis showed that chromosomal abnormalities of 1p36 and 9p21 in invasive SCC were as frequent as those in early SCC. There was no statistical difference in expression levels of TAp73 and p16 protein between early SCC and invasive SCC. Brambilla et al suggested that the expression of p16 protein in invasive NSCLC was lower than that of preinvasive lesions, including mild to severe dysplasia and CIS. They suggested that a loss of p16 protein might precede the acquisition of invasive behavior of NSCLC (56). In our data, no statistical difference was found in expressions of p16 protein between early and invasive SCC. This result suggests that the loss of p16 protein and LOH/MSI of 9p21 are early events in the carcinogenesis of bronchogenic cancer.

The PDS-2000 AFB system was able to detect abnormal auto-fluorescence even in such precancerous lesions, including squamous dysplasia. Moderate or severe dysplastic lesions that emit abnormal autofluorescence might be treated by bronchoscopical approach such as PDT because, as shown in the present study, these lesions already have chromosomal abnormalities similar to those of early and invasive SCC.

Acknowledgements

We are grateful to Mr. Masatoshi Sado and Mr. Shizuo Kato at Ashahikawa Medical College Hospital Surgical Pathology Service for preparing immunohistochemical staining and thin slice sections for microdissection.

References


